The peer-reviewed study, entitled “US Cannabis Laws Projected To Cost Generic And Brand Pharmaceutical Firms Billions”, analyzed how publicly traded pharmaceutical firms fared after adult-use or medical marijuana laws were enacted by states. According to Ziemowit Bednarek, California Polytechnic State University’s Finance Department, together with Sarah Stith, pharmaceutical stocks were worth 1.5-2% lower in only 10 days following cannabis legalization.
New aggregated polls reveal that 55% of respondents believe marijuana is not dangerous, and a…
Every Croptober, growers waste time on folklore instead of physics. We break down the science…
Leafly's 2026 cannabis voter guide for the midterms is the only plan you need to…
Come along on an Emerald Triangle road trip with Lindsay MaHarry to see some of…
This month an Iowa church got what every sacramental-plant congregation dreams about: a path to…
The cannabis industry does not need another study, another tax revenue report, or another state-level…